KWAME OSEI, M. D.; THOMAS M. O'DORISIO, M.D.
Various therapies have been used to treat patients with active malignant insulinoma (1-3), which comprises 10% of all beta-cell tumors of the pancreas (1). Somatostatin, a tetradecapeptide found in the hypothalamus and gastro-entero-pancreatic system, suppresses several endocrine hormones (4). However, because of the short halflife (5 to 10 minutes) of endogenous somatostatin, several analogs with longer-acting properties have been synthesized (5). Recently, compound 201-995 (Sandoz Pharmaceutical, Inc., East Hanover, New Jersey), an octapeptide with a 10 to 20 times longer half-life and a 50 to 100 times greater potency has become available in United States. We report the use of
KWAME OSEI, THOMAS M. O'DORISIO. Malignant Insulinoma: Effects of a Somatostatin Analog (Compound 201-995) on Serum Glucose, Growth, and Gastro-Entero-Pancreatic Hormones. Ann Intern Med. 1985;103:223–225. doi: 10.7326/0003-4819-103-2-223
Download citation file:
Published: Ann Intern Med. 1985;103(2):223-225.
Cardiology, Coronary Risk Factors, Diabetes, Endocrine and Metabolism, Gastroenterology/Hepatology.
Results provided by:
Copyright © 2017 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use